Portal de Periódicos da CAPES

Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection

2023; Oxford University Press; Volume: 78; Issue: 4 Linguagem: Inglês

10.1093/cid/ciad695

1537-6591

Antoine Bachelard, Quentin Le Hingrat, Valentine-Marie Ferré, Minh Patrick Lê, Gilles Peytavin, Florence Damond, Charlotte Charpentier, Guillemette Fremont Goudot, Jeanne Goupil de Bouillé, Sylvie Lariven, Pierre Delobel, Yazdan Yazdanpanah, Diane Descamps, Sophie Matheron, Jade Ghosn, Jade Ghosn, Sophie Matheron, Victor Appay, Brigitte Autran, V. Conte, Ventzislava Petrov–Sanchez, Chloé Birklé, Rémi Cheynier, Françoise Brun‐Vézinet, Geneviève Chêne, Anne Hosmalin, Y Khalil, Brigitte Autran, Diane Descamps, Serge Eholié, Didier Ekouvie, Loretxu Pinoges, Trust Saidi, Linda Wittkop, Abdoul Karim Sangaré, Michaela Müller‐Trutwin, Alexandra Ozanne, Ventzislava Petrov–Sanchez, Gilles Peytavin, Céline Roy, Asier Sáez‐Cirión, François Simon, C. Lascoux, M.C. Meyohas, Karine Lacombe, Dominique Salmon‐Céron, Agathe Rami, Gilles Pialoux, Sophie Matheron, Jade Ghosn, Roland Tubiana, P. de Truchis, Marie-Aude Khuong-Josses, Ouda Derradji, Didier Troisvallet, Julie Timsit, Anne-Sophie Lascaux, Vincent Jeantils, Olivier Bouchaud, O. Patey, Pauline Caraux-Paz, Cécile Goujard, Laurence Gérard, Emmanuel Mortier, Eric Froguel, Charlotte Welker, V. Daneluzzi, Philippe Genet, A. Leprêtre, David Zucman, Gilles Force, Anne Coutellier-Simon, Jean‐François Deleuze, Laurence Weiss, Valérie Garrait, H Colin, L. Blum, Pr jean-Daniel Lelièvre, Anne Dulioust, Véronique Perrone, Christophe Billy, Cécile Winter, I Aupérin, I. Torre, Jean‐Michel Molina, Patrick Brunet, S Lamy, Alain Devidas, Amélie Chabrol, Elisabeth Rouveix, S Kernbaum, Claudine Duvivier, Marie‐Anne Bouldouyre, Loïc Bodard, Patrick Imbert, C. Rapp, François Boué, Agnès Uludag, F. Chaix, Olivia Son, Olivier Bouchaud, J. P. Viard, Xavier Duval, A. Greder Belan, V. Grégoire, Geneviève Beck-Wirth, F. Raffi, C Drobacheff, Catherine Chirouze, Thierry Allègre, Renaud Verdon, Isabelle Poizot-Martin, Corinne Daniel, Moise Machado, Anne-Lise Lecapitaine, Pr Bruno Marchou, Pierre Delobel, Louis Bernard, Yasmine Debab, Pascale Leclercq, Joëlle Julien, Jacques Moreau, Isabelle Ravaux, Cédric Arvieux, Christophe Michaud, Djamila Makhloufi, Gwenael Lemoal, Philippe Arsac, Thierry Prazuck, Alain Lafeuillade, Benoît Martha, Philippe Van de Perre, Faïza Ajana, Philippe Morlat, Erwan Brottier, M. Dupon, Didier Neau, jean-Luc Pellegrin, Isabelle Raymond‐Letron, N Montagne, Thierry May, H. Wille, Y. Douadi, Jacques Reynes, J. L. Schmit, C. Rouger, Jean‐Luc Berger, Yves Poinsignon, Christine Jacomet, Lionel Piroth, Eric S. Rosenthal, D. Garipuy, Martin Michaud, Agnès Riché, François Prevoteau du Clary, A. Naqvi, J. Gaillat, David Rey, François Abino, P. Mercié, Philippe Morlat, Pierre-Marie Roger, E. Aïssi, Jean-Marie Chennebault, Dominique Liné, Narimamy Randrianasolo, Catherine Merle, Patricia Granet, L. Caunegre, L Cotte, Laurianne Boileau, Jean-Batiste Euzen, Pascale Perfezou, Nicolas Lefèbvre, Jean‐Philippe Talarmin, Catherine Chirouze, Simona Pavel, B. Ponceau, Julien Saison, Albert Sotto, Didier Laureillard, Anne Vandendriessche, Iuliana Darasteanu, Chloé Birklé, Ventzislava Petrov–Sanchez, Trust Saidi, Abdoul Karim Sangaré, Chloé Birklé, Ventzislava Petrov–Sanchez, Tounes Saidi, Abdoul Karim Sangaré, V. Conte, Nathalie Chaghil-Boissière, Geneviève Chêne, Y Khalil, Valérie Conte, M Dembélé, Loretxu Pinoges, Y Khalil, Linda Wittkop, Alexandra Ozanne, Maxime Pallier, Loretxu Pinoges, Céline Roy, C. Lascoux, Solaya Chalal, Lynda Oualit, Leia Becam, Céline Roy, Carine Lascoux, Lydia Leger, Matthieu Legoff, Isabelle Pellegrin, Rémi Cheynier, Françoise Brun‐Vézinet, Brigitte Autran, Diane Descamps, Lara Youssef, Rémi Cheynier, Vincent Vieillard, Brigitte Autran, Rémi Cheynier, Gianfranco Pancino, Anne Hosmalin, Vincent Vieillard, Victor Appay, Vincent Vieillard, Asier Sáez‐Cirión,

Hepatitis C virus research

Abstract We evaluated Ibalizumab (IBA)-containing standardized optimized salvage regimen (with or without a 4-week foscarnet induction) in individuals harboring multidrug-resistant human immunodeficiency virus type 2 (HIV-2). Nine were included; 2 achieved virological suppression after foscarnet induction with a sustained suppression at Week 24 after IBA initiation, and an additional individual at Week 24 after Ibalizumab initiation.